Cinarizine - instructions for use, dose, side effects, contraindications

Excipients: lactose monohydrate (milk sugar) - 102.41 mg; potato starch - 16.0 mg; povidone (polyvinylpyrrolidone, medium molecular weight) - 3.23 mg; silicon dioxide colloid (aerosil) - 2.36 mg; magnesium stearate -1.0 mg.

Description:

Tablets are white or white with a creamy hue of a flat-cylindrical shape with a facet and a risk.

Pharmacotherapeutic group:The blocker of "slow" calcium channels.

ATX: & nbsp

N.07.C.A.02 Cinnarizine

Pharmacodynamics:

The selective blocker of "slow" calcium channels, reduces the intake of calcium into the cells and reduces their concentration in the depot of the plasmolemma, reduces the tone of the smooth muscles of arterioles, strengthens the vasodilating effect of carbon dioxide. Immediately affecting the smooth muscles of blood vessels, reduces their response to nutrients (adrenaline, norepinephrine, dopamine, angiotensin II, vasopressin).

It has a vasodilating effect (especially with respect to cerebral vessels), not having a significant effect on blood pressure. Moderately blocks H1-histamine receptors, reduces the excitability of the vestibular apparatus, reduces the tone of the sympathetic nervous system. Effective in patients with initial atherosclerosis of cerebral vessels and chronic diseases of blood vessels, brain with postinsultaneous focal symptoms. In patients with impaired peripheral circulation, improves blood supply to organs and tissues (including myocardium), enhances postischemic vasodilation.

Pharmacokinetics:

The time required to reach the maximum concentration is 1-3 hours, the connection with plasma proteins is 91%.Completely metabolized in the liver (via dealkylation). The half-life is 4 hours. It is excreted as metabolites: 1/3 - by the kidneys and 2/3 - with the calves.

Indications:

Chronic cerebrovascular insufficiency (dizziness, tinnitus, headache, memory impairment, decreased concentration of attention).

Vestibular disorders - (including Meniere's disease, dizziness, tinnitus, nystagmus, nausea and vomiting of a labyrinthine origin).

Prevention of kinetosis ("road disease" - sea and air sickness).

Migraine (prevention of seizures).

Violations of the peripheral circulation, ("intermittent" lameness, Raynaud's disease, diabetic angiopathy, thrombophlebitis, trophic disorders, including trophic and varicose ulcers).

Contraindications:

Hypersensitivity to the components of the drug, children under 5 years of age, lactose intolerance, lactase deficiency, glucose-galactose malabsorption syndrome.

Carefully:

Parkinson's disease.

Pregnancy and lactation:

The use of the drug during pregnancy and during breastfeeding is contraindicated.

Dosing and Administration:

Inside, after eating.

For chronic cerebrovascular insufficiency - 25 mg 3 times a day. Children older than 5 years - 12.5 mg 3 times a day. The course of treatment is from several weeks to several months, depending on the condition of the patient.

If peripheral circulation is disturbed - 50-75 mg 3 times a day. Children older than 5 years - 25-50 mg 3 times a day. The course of treatment is from several weeks to several months, depending on the condition of the patient.

For the prevention of sea and air sickness - 25 mg for 30 minutes before the forthcoming trip, if necessary, dose reception is repeated after 6 hours; for children from 5 years - 1/2 dose for adults.

With vestibular disorders - 25 mg 3 times a day. Children dose reduced by 2 times. The course of treatment is from several weeks to several months, depending on the condition of the patient.

For the prevention of migraine attacks - 25 mg 3 times a day. The course of treatment is from several weeks to several months, depending on the condition of the patient.

The maximum daily dose should not exceed 225 mg. With high sensitivity to the drug, treatment starts with 1/2 dose, increasing it gradually.

To achieve the optimal therapeutic effect, the drug should be taken continuously.

Side effects:

From the nervous system: drowsiness, fatigue, headache), extrapyramidal disorders (tremor of limbs and increased muscle tone, hypokinesia), depression.

From the digestive system: dryness of the oral mucosa, pain in the epigastric region, dyspepsia, cholestatic jaundice.

From the skin: increased sweating, red flat lichen.

Allergic reactions: skin rash.

Other: decrease in blood pressure, increase in weight, body, lupus-like syndrome.

Overdose:

Symptoms: vomiting, drowsiness, tremor, excessive lowering of blood pressure, coma. Treatment: there is no specific antidote, gastric lavage, Activated carbon, symptomatic therapy.

Interaction:

Strengthens the action of ethanol, sedatives, tricyclic antidepressants.

Special instructions:

In connection with the presence of H1-histamine-blocking effect cinnarizine can affect the result in the anti-doping control of athletes (false positive result), as well as give false-negative results in conducting skin diagnostic tests (4 days before the study treatment should be canceled).

With prolonged use, it is recommended that a check examination of liver function, kidney function, and peripheral blood picture is recommended.

Women receiving cinnarizine, breast-feeding is not recommended.

Patients with Parkinson's disease should be prescribed only in cases where the benefits from its administration exceed the possible risk of deterioration.

Effect on the ability to drive transp. cf. and fur:

During the treatment period, care must be taken when driving vehicles and working with mechanisms requiring increased attention.

Form release / dosage:

Tablets 25 mg.

Packaging:

For 10 or 25 tablets in a contour mesh package. 5 contour cell packs of 10 tablets or 2, 4 contour packs of 25 tablets together with instructions for use are placed in a pack of cardboard.

Storage conditions:

In a dry, the dark place at a temperature of no higher than 25 ° C.

Keep out of the reach of children!

Shelf life:

2 years. Do not use after the expiry date printed on the package.

Terms of leave from pharmacies:On prescription

Registration number:LS-001635

Date of registration:02.06.2006

The owner of the registration certificate:TATHIMFARMPREPARATY, JSC TATHIMFARMPREPARATY, JSC Russia

Manufacturer: & nbsp

TATHIMFARMPREPARATY, JSC Russia

Information update date: & nbsp08.10.2015

Illustrated instructions

Instructions

Cinnarizine (Cinnarizin)